<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5112">
  <stage>Registered</stage>
  <submitdate>17/06/2015</submitdate>
  <approvaldate>17/06/2015</approvaldate>
  <nctid>NCT02480296</nctid>
  <trial_identification>
    <studytitle>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of MYK-461 in Healthy Volunteers</studytitle>
    <scientifictitle>A Phase 1, Double-blind, Randomized, Placebo-controlled, Ascending Multiple Oral Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MYK-461 in Healthy Volunteers</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>MYK461-003</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - MYK-461
Treatment: drugs - Placebo

Experimental: MYK-461 - Oral Tablet x 28 days

Placebo Comparator: Placebo - Oral Tablet x 28 days


Treatment: drugs: MYK-461


Treatment: drugs: Placebo
Placebo comparator

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety as measured by the incidence of adverse events - Incidence of adverse events</outcome>
      <timepoint>63 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Determination of pharmacokinetic parameters - maximum concentration (Cmax)</outcome>
      <timepoint>63 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Determination of pharmacokinetic parameters - time of the maximum measured concentration (Tmax)</outcome>
      <timepoint>63 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Determination of pharmacokinetic parameters - area under the concentration time curve (AUC)</outcome>
      <timepoint>63 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Determination of pharmacokinetic parameters - half-life (t1/2)</outcome>
      <timepoint>63 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Characterize pharmacodynamic parameters - echocardiogram assessment</outcome>
      <timepoint>63 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Characterize pharmacodynamic parameters - peak oxygen consumption</outcome>
      <timepoint>63 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Normal body mass index (BMI)

          -  Normal LVEF

          -  Normal electrocardiogram (ECG)

          -  Females must be non pregnant, non lactating and, if sexually active, be using an
             acceptable birth control method from the time of first dose through 3 months after the
             last dose of study drug</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Any structural abnormalities on echocardiography

          -  Positive results of HIV test and/or seropositive for HCV or HBV</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>60</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Nucleus Network - Melbourne</hospital>
    <postcode> - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>MyoKardia, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to establish safety, tolerability, pharmacokinetics and
      pharmacodynamics of multiple doses of MYK-461 in human subjects. This is a randomized,
      double-blind, placebo-controlled, sequential group, multiple ascending (oral tablet) dose
      study in healthy volunteers aged 18-55 years.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02480296</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Michael Grimm, MD</name>
      <address>MyoKardia, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>